[
  {
    "ts": null,
    "headline": "Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?",
    "summary": "MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.",
    "url": "https://finnhub.io/api/news?id=d442286596621996ceafd5dc69f37ccb03f38b5bdff8a45c6c1d96394132cfec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754926320,
      "headline": "Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?",
      "id": 136310504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.",
      "url": "https://finnhub.io/api/news?id=d442286596621996ceafd5dc69f37ccb03f38b5bdff8a45c6c1d96394132cfec"
    }
  },
  {
    "ts": null,
    "headline": "Wasatch Global Value Fund Q2 2025 Commentary",
    "summary": "The Wasatch Global Value FundâInvestor Class returned 5.69% in the quarter, slightly underperforming the MSCI AC World Value Index, which returned 5.84%.",
    "url": "https://finnhub.io/api/news?id=0d237a15b93b61b690ce7b4e090cc715672c9b063b8df0714337e96a2aec5daf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754920680,
      "headline": "Wasatch Global Value Fund Q2 2025 Commentary",
      "id": 136303489,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161777481/image_2161777481.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Wasatch Global Value FundâInvestor Class returned 5.69% in the quarter, slightly underperforming the MSCI AC World Value Index, which returned 5.84%.",
      "url": "https://finnhub.io/api/news?id=0d237a15b93b61b690ce7b4e090cc715672c9b063b8df0714337e96a2aec5daf"
    }
  },
  {
    "ts": null,
    "headline": "Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus",
    "summary": "Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.",
    "url": "https://finnhub.io/api/news?id=3d1236c9359ec5d2fd76679e31a6e2fb86d6d808c70f325b77bd33bfd62049e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754912580,
      "headline": "Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus",
      "id": 136294246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.",
      "url": "https://finnhub.io/api/news?id=3d1236c9359ec5d2fd76679e31a6e2fb86d6d808c70f325b77bd33bfd62049e2"
    }
  },
  {
    "ts": null,
    "headline": "Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities",
    "summary": "Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks due to strong fundamentals and future AI benefits. Read more here",
    "url": "https://finnhub.io/api/news?id=256ea8bb2e23b7ca971a343047437044e07eec4a066f579cd2fa3dc2bb15f49b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754907483,
      "headline": "Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities",
      "id": 136294096,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks due to strong fundamentals and future AI benefits. Read more here",
      "url": "https://finnhub.io/api/news?id=256ea8bb2e23b7ca971a343047437044e07eec4a066f579cd2fa3dc2bb15f49b"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth",
    "summary": "Multiple Myeloma is a cancer affecting plasma cells in bone marrow, often leading to weakened bones, anemia, and kidney damage. The production of abnormal M-proteins is a disease hallmark, detectable in blood or urine. While incurable, treatment advancements like chemotherapy, immunotherapy, and CAR T-cell therapy enhance patient outcomes. Market growth is driven by innovative immunotherapies, yet challenges like high treatment costs, resistance, and late diagnosis persist. Key players such as J",
    "url": "https://finnhub.io/api/news?id=9b792f2d80db8c118ae6948862869b5f26d134d3d1926bdd311f297bfab8402d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754905080,
      "headline": "Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth",
      "id": 136292450,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Multiple Myeloma is a cancer affecting plasma cells in bone marrow, often leading to weakened bones, anemia, and kidney damage. The production of abnormal M-proteins is a disease hallmark, detectable in blood or urine. While incurable, treatment advancements like chemotherapy, immunotherapy, and CAR T-cell therapy enhance patient outcomes. Market growth is driven by innovative immunotherapies, yet challenges like high treatment costs, resistance, and late diagnosis persist. Key players such as J",
      "url": "https://finnhub.io/api/news?id=9b792f2d80db8c118ae6948862869b5f26d134d3d1926bdd311f297bfab8402d"
    }
  },
  {
    "ts": null,
    "headline": "Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations",
    "summary": "The Non-metastatic Prostate Cancer market is witnessing substantial growth driven by increasing demand for targeted therapies and innovative treatment options. Non-metastatic prostate cancer, confined to the prostate gland, benefits from early detection methods like PSA testing and multiparametric MRI, facilitating timely intervention. Key players like Johnson & Johnson, Astellas Pharma, and Pfizer are pioneering advancements with androgen receptor inhibitors and precision medicine. Despite sign",
    "url": "https://finnhub.io/api/news?id=7ed66726fb860b103f275cf311c614095bcaca667705b72b586e98df5fdd96f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754903580,
      "headline": "Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations",
      "id": 136292298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Non-metastatic Prostate Cancer market is witnessing substantial growth driven by increasing demand for targeted therapies and innovative treatment options. Non-metastatic prostate cancer, confined to the prostate gland, benefits from early detection methods like PSA testing and multiparametric MRI, facilitating timely intervention. Key players like Johnson & Johnson, Astellas Pharma, and Pfizer are pioneering advancements with androgen receptor inhibitors and precision medicine. Despite sign",
      "url": "https://finnhub.io/api/news?id=7ed66726fb860b103f275cf311c614095bcaca667705b72b586e98df5fdd96f9"
    }
  }
]